Locus 55: SLC22A1|SLC22A2 (6q25.3)
EA = effect allele; OA = other allele; EAF = frequency of effect allele;
| Summary of biological annotations |
| SNP | rs662138 |
| Chromosomal location | Chr6: 160,484,466 (6q25.3) |
| Gene (distance) | SLC22A1 (0) |
| Predicted causal gene | SLC22A1 |
| Gene/protein classification | transporter/transporter |
| Metabolite (Pathway) | isobutyrylcarnitine (Valine, leucine and isoleucine metabolism; Amino acid) |
| Biochemical locus-metabolite relationship | SLC22A1 and SLC22A2 encode the Oct1 and Oct2 organic cation transporters. Perhaps isobutyrylcarnitine or a related metabolite is a substrate [9260930]. |
| eQTL associations | - |
| Medical information |
| Complex trait associations | Cholesterol, total [20686565]; LDL cholesterol [20686565] |
| Known metabolite associations | isobutyrylcarnitine [21886157] |
| Inborn error of metabolism | - |
| Pharmacological information |
| ChEMBL ID | CHEMBL5685, CHEMBL1743122 |
| Drug information |
Substrates of SLC22A1: Tetraethylammonium, N-methylpyridinium, metformin*, oxaliplatin; Inhibitors of SLC22A1: Quinine, quinidine, disopyramide; Substrates of SLC22A2: N-Methylpyridinium, tetraethylammonium, metformin*, pindolol, procainamide, ranitidine amantadine, amiloride, oxaliplatin, varenicline; Inhibitors of SLC22A2: Cimetidine*, pilsicainide, cetirizine*, testosterone, quinidine; (PMID: 20190787)
|
| Locus information for top associated metabolite |
HapMap2 imputation | 1KGP imputation |

